MV 833

Drug Profile

MV 833

Alternative Names: Anti-vascular endothelial growth factor monoclonal antibody - Toagosei; Anti-VEGF monoclonal antibody - Toagosei; huMV 833; SMART anti-VEGF; SMART anti-VEGF monoclonal antibody

Latest Information Update: 07 May 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toagosei
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Feb 2001 A phase I study has been added to the Cancer pharmacodynamics and adverse events sections
  • 07 Dec 2000 Discontinued - Phase-I for Solid tumours in Europe (unspecified route)
  • 07 Dec 2000 Discontinued - Preclinical for Solid tumours in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top